1/4 of patients on highest investigational doses of CP-690,550 achieve ACR70 at week 12
Copenhagen, Denmark, Thursday 11 June 2009: A quarter of active rheumatoid arthritis (RA) patients receiving either 10mg (24.6%) or 15mg (28.1%) twice daily of the investigational oral JAK-3 (janus-associated kinase) inhibitor CP-690,550 (CP) achieved ACR70* after 12 weeks, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. The primary outcome for the study was ACR20*, with 75.4% of patients achieving this measure at 12 weeks for both 10mg and 15mg doses. The study also showed that, comparatively, the ACR70* responses for adalimumab (ADA, a monoclonal antibody and anti-TNF) and placebo, were 3.8% and 5.1% respectively at the same follow up point.
At the 12 week interim analysis, three doses (5mg, 10mg and 15mg twice daily) of CP demonstrated statistical superiority to placebo in nearly all clinical outcomes measured, including: ACR20, HAQ-DI** and DAS28***, in patients who had had a previously inadequate response to a DMARD (disease-modifying anti-rheumatic drug). Of patients receiving 15mg twice daily CP, 75.4% achieved ACR20 and 40.4% reached DAS28 remission; compared with 47.2% of ADA and 28.8% of placebo patients for ACR20; and 4.4% of ADA and 6.7% of placebo patients for DAS28 remission respectively.
Dr Roy Fleischmann, Clinical Professor of Medicine, University of Texas, Dallas, USA who led the study, said: "The development of oral small-molecule JAK inhibitors, such as CP which targets the JAK-1/3 enzyme pathway, represents a new approach in the treatment of RA. These drugs offer the potential for more precise targeting than existing oral DMARD treatments, in addition to a more convenient oral administration than biologic treatments. The results of this study would suggest that the compound appears worthy for future phase III investigation."
In the 6-month double-blind phase IIb dose-ranging study, 384 patients were randomised to various trial doses of oral CP: 1mg, 3mg, 5mg, 10mg and 15mg twice daily; or to ADA 40mg subcutaneous injection every other week for 12 weeks followed by CP 5mg twice daily or placebo.
The most frequently-reported CP treatment-emergent all-cause AEs were urinary tract infections (4.4%), diarrhoea (4.0%), bronchitis (3.7%), and headache (3.7%). Most frequently-reported ADA treatment-emergent all-cause AEs were bronchitis and pruritus (5.7% each), and blood creatinine increase, dizziness, headache, influenza, nausea, rash, and swelling (3.8% each).
The inclusion criteria for the study were as follows: patients with active RA (6 tender joints and 6 swollen joints (66/68 joint count)), and CRP (c-reactive protein) >7 mg/dL or ESR (erythrocyte sedimentation rate) > ULN). 87% of the 384 patients who were randomised to receive a study drug were female, with mean baseline value ranges as follows: age 52.4 - 55.1 years; disease duration 7.7 - 11.0 years; HAQ DI 1.4 - 1.6; DAS28-3 (CRP) 5.4 - 5.6; and 70 - 83% RF positive. The data presented at EULAR are taken from a week 12 interim analysis of the 6-month study and include efficacy and safety assessments taken at weeks: 2, 4, 6, 8, 10, and 12. The HAQ-DI response was classified as a 0.22 unit improvement from baseline, and DAS28 remission was set at DAS28-3 (CRP) achieving < 2.6.
Oral JAK inhibitors are also currently being investigated for a variety of other therapeutic uses, including: other autoimmune diseases (such as multiple sclerosis and psoriasis), prevention of organ rejection following transplant and certain cancers.
Articles on the same topic
- Canakinumab shows promising efficacy and tolerability in children with systemic JIAMon, 15 Jun 2009, 9:37:34 EDT
- Increased levels of certain cytokines and chemokines predict onset of rheumatoid arthritisMon, 15 Jun 2009, 9:37:33 EDT
- Tracking levels of key biomarkers reflects disease activity and progression of rheumatoid arthritisMon, 15 Jun 2009, 9:37:32 EDT
- RA individuals from lower GDP countries keep working despite worse symptoms than richer countriesFri, 12 Jun 2009, 15:39:40 EDT
- Over half of people with rheumatoid arthritis have periodontitisFri, 12 Jun 2009, 15:39:36 EDT
- Better access to info and dialogue with HCPs on sexual issues for rheumatology patientsFri, 12 Jun 2009, 10:08:58 EDT
- 63 percent of RA patients suffer psychiatric disorders, with depressive spectrum conditions most likelyFri, 12 Jun 2009, 10:08:55 EDT
- Diagnosis of arthritis 5 years earlier in childless women compared to those with childrenFri, 12 Jun 2009, 10:08:52 EDT
- New treatment strategy offers hope to RA patients who failed all other therapiesFri, 12 Jun 2009, 10:08:42 EDT
- Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritisFri, 12 Jun 2009, 10:08:37 EDT
- Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patientsFri, 12 Jun 2009, 9:44:14 EDT
- Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus modelsThu, 11 Jun 2009, 10:58:51 EDT
- Tracking levels of key biomarkers reflects disease activity and progression of rheumatoid arthritisfrom PhysorgMon, 15 Jun 2009, 11:14:53 EDT
- Canakinumab shows promising efficacy and tolerability in children with systemic JIAfrom Science BlogMon, 15 Jun 2009, 9:35:30 EDT
- Increased levels of certain cytokines and chemokines predict onset of rheumatoid arthritisfrom Science BlogMon, 15 Jun 2009, 9:35:30 EDT
- Tracking levels of key biomarkers reflects disease activity and progression of rheumatoid arthritisfrom Science BlogMon, 15 Jun 2009, 9:35:28 EDT
- RA individuals from lower GDP countries keep working despite worse symptoms than richer countriesfrom PhysorgFri, 12 Jun 2009, 17:28:52 EDT
- Over Half Of People With Rheumatoid Arthritis Have Periodontitisfrom Science DailyFri, 12 Jun 2009, 15:35:57 EDT
- New Approach To Prevent Antibody-mediated Damage In Kidney Transplantsfrom Science DailyMon, 8 Jun 2009, 22:21:35 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Big box stores could ditch the grid, use natural gas fuel cells instead
- Study simulates changes to admissions criteria for NYC's specialized high schools
- Study finds significant facial variation in pre-Columbian South America
- Researchers find 3-D printed parts provide low-cost, custom alternatives for lab equipment
- Protecting crops from radiation-contaminated soil